Trial Profile
Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2090314 (Primary) ; Carboplatin; Pemetrexed
- Indications Cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 20 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 20 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.